Loading…
DIA Europe 2019 has ended
View analytic
Wednesday, February 6 • 15:15 - 16:15
#S0203: Precision Medicine: Gene-Editing, Advance Therapies and Personalised Medicine

Sign up or log in to save this to your schedule and see who's attending!

Tweet Share
Component Type: Session

Precision medicine is the present and future of tailored therapies. This session covers 3 important aspects of precision medicine: 1) Precision in genome editing using e.g. Crisp/Cas technology allows us to modify cells and use them to treat cancer, infectious disease and hematological conditions. 2) With precision medicine, treatment choice and benefit-risk assessment will have to rely on new and more individualised methods, such as generalised pairwise comparisons of patient outcomes. 3) Genomics on a population scale may be used to identify individual disease risks and suitability of preventive measures, even before the onset of disease.

Chair

Klaus Cichutek, PhD

Speaker

Overview of Current Gene Editing Landscape
Tatiana Anna Reimer, PhD

The Future of Personalised Medicine – Exploring the Successes and Challenges
Kristiina Rosin

From Precision to Personalised Medicine: Generalised Pairwise Comparisons as a Tool to Individualise Treatment Choices
Everardo Saad, MD


Speakers
avatar for Klaus Cichutek

Klaus Cichutek

President, Paul-Ehrlich-Institut
Prof. Dr. Klaus CICHUTEK is the President of the Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, in Germany. PEI is a senior federal agency reporting to the German Federal Ministry of Health and member of the network of the European regulatory authorities united... Read More →
avatar for Tatiana Reimer

Tatiana Reimer

Regulatory Affairs Strategist, Bayer
Tatiana Anna Reimer is a Global Regulatory Strategist (GRS) at Bayer AG. As GRS, Tatiana is responsible for a regulatory strategy of development and marketed products in ophthalmic, haemophilia and pulmonary diseases. In addition, she is providing operational and strategic expertise... Read More →
avatar for Kristiina Rosin

Kristiina Rosin

Regulatory Policy & Intelligence Manager, Abbvie Ltd
Kristiina is a Regulatory Policy and Intelligence Manager at AbbVie Ltd with a focus on medical devices and personalised medicine in the EU. Prior to joining AbbVie in 2014 Kristiina held labelling and regulatory positions at Pfizer and Alltech. Kristiina holds a BSc(Hons) degree... Read More →
ES

Everardo Saad

Medical Director, IDDI
Everardo Saad is a medical oncologist with a special interest in clinical-trial methodology. He graduated in Medicine and trained in Internal Medicine in Sao Paulo, Brazil, and pursued a fellowship in Medical Oncology at the University of Texas M.D. Anderson Cancer Center, in Houston... Read More →

Wednesday February 6, 2019 15:15 - 16:15
K2 Austria Center Vienna Bruno-Kreisky-Platz 1 1220 Vienna Austria
  02 Evolution of Science and Policy, Session
  • Featured Topics Translational Medicine
  • Tags Session